Evidence map›Paper›PMID 41275259›Full record

ArticleJournal of biological engineering2025

The construction of the gelatin methacrylate microneedle -encapsulated newcastle disease virus and its antitumor effect in hepatocellular carcinoma.

Tong Li, Xiyu Liu, Jintong Na, Shixu Fang, Liping Zhong, Yongxiang Zhao

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of biological engineering, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Tong LiInstitute of State Key Laboratory of Targeting Oncology, National Center for International Research of Bio-targeting Theranostics, Guangxi Key Laboratory of Bio-targeting Theranostics, Collaborative Innovation Center for Targeting Tumor Diagnosis and Therapy, Guangxi Medical University, Nanning, Nanning, Guangxi, 530021, China.
Xiyu LiuInstitute of State Key Laboratory of Targeting Oncology, National Center for International Research of Bio-targeting Theranostics, Guangxi Key Laboratory of Bio-targeting Theranostics, Collaborative Innovation Center for Targeting Tumor Diagnosis and Therapy, Guangxi Medical University, Nanning, Nanning, Guangxi, 530021, China.
Jintong NaInstitute of State Key Laboratory of Targeting Oncology, National Center for International Research of Bio-targeting Theranostics, Guangxi Key Laboratory of Bio-targeting Theranostics, Collaborative Innovation Center for Targeting Tumor Diagnosis and Therapy, Guangxi Medical University, Nanning, Nanning, Guangxi, 530021, China.
Shixu FangInstitute of State Key Laboratory of Targeting Oncology, National Center for International Research of Bio-targeting Theranostics, Guangxi Key Laboratory of Bio-targeting Theranostics, Collaborative Innovation Center for Targeting Tumor Diagnosis and Therapy, Guangxi Medical University, Nanning, Nanning, Guangxi, 530021, China.
Liping ZhongInstitute of State Key Laboratory of Targeting Oncology, National Center for International Research of Bio-targeting Theranostics, Guangxi Key Laboratory of Bio-targeting Theranostics, Collaborative Innovation Center for Targeting Tumor Diagnosis and Therapy, Guangxi Medical University, Nanning, Nanning, Guangxi, 530021, China. zhongliping@gxmu.edu.cn.
Yongxiang ZhaoInstitute of State Key Laboratory of Targeting Oncology, National Center for International Research of Bio-targeting Theranostics, Guangxi Key Laboratory of Bio-targeting Theranostics, Collaborative Innovation Center for Targeting Tumor Diagnosis and Therapy, Guangxi Medical University, Nanning, Nanning, Guangxi, 530021, China. zhaoyongxiang@gxmu.edu.cn.

Funding

The Scientific and Technological Innovation Major Base of Guangxi No.2022-36-Z05
6 · The paper itself

Abstract

backgroundHepatocellular carcinoma (HCC) is associated with one of the highest cancer-related mortality rates worldwide and remains therapeutically challenging. There is an urgent need for innovative treatment strategies. Although Newcastle disease virus (NDV) has demonstrated potent oncolytic activity in vitro and in animal models, free virions administered intravenously are rapidly neutralized by pre-existing antibodies and exhibit poor tumor tropism, significantly limiting their clinical translation (Shalhout et al., Nat Rev Clin Oncol 20(3):160-177, 2023).

objectivesThis study aimed to develop porous gelatin methacrylate (GelMA) microneedles (MNs) for encapsulating Newcastle disease virus (NDV) and to evaluate their antitumor efficacy against HCC.

methodsGelMA microneedles were fabricated and screened across a concentration gradient for biocompatibility and degradability. The optimal NDV-loaded formulation was subsequently evaluated for safety and therapeutic efficacy in HCC models using in vitro assays and a subcutaneous HCC xenograft model in nude mice.

resultsMicroneedles prepared with 10% (w/v) GelMA exhibited excellent biocompatibility and degradability. 10% GelMA MNs loaded with an NDV-gelatin mixture sustained NDV release for over 24 h. Compared with the free virus, they induced significantly stronger inhibition of proliferation, migration, and invasion, and promoted greater apoptosis in HCC cells. In mice bearing subcutaneous HCC xenografts, NDV encapsulated in 10% GelMA MNs markedly suppressed tumor growth without significant changes in body weight or histological damage to major organs. Histological analysis further confirmed reduced proliferation and increased apoptosis in the treated group.

conclusionGelMA-encapsulated NDV microneedles represent a novel, promising and well-tolerated therapeutic strategy for HCC.

Indexed as

Gelatin methacrylateHepatocellular carcinomaHydrogelMicroneedleNewcastle disease virus

Identifiers

PMID41275259
PMCPMC12751726

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.